172 related articles for article (PubMed ID: 17692685)
21. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy.
Dittrich E; Schmaldienst S; Soleiman A; Hörl WH; Pohanka E
Transpl Int; 2004 May; 17(4):215-20. PubMed ID: 15112032
[TBL] [Abstract][Full Text] [Related]
23. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
Yakupoglu YK; Buell JF; Woodle S; Kahan BD
Transplant Proc; 2006 Mar; 38(2):358-61. PubMed ID: 16549120
[TBL] [Abstract][Full Text] [Related]
24. Regression of post-transplant Kaposi's sarcoma using sirolimus.
Kolhe N; Mamode N; Van der Walt J; Pattison J
Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH
J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
[TBL] [Abstract][Full Text] [Related]
26. [Malignant neoplasias in renal transplantation recipients].
Gómez-Roel X; León-Rodríguez E
Rev Invest Clin; 2005; 57(2):225-9. PubMed ID: 16524062
[TBL] [Abstract][Full Text] [Related]
27. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
28. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
29. [Skin cancer in renal transplant recipients].
Mangino M; Schena FP
G Ital Nefrol; 2010; 27 Suppl 50():S75-80. PubMed ID: 20922700
[TBL] [Abstract][Full Text] [Related]
30. Mucosa-associated lymphoid tissue gastric lymphoma regression in a renal transplant patient after conversion of the immunosuppression to sirolimus: a case report.
Lasmar EP; Coelho LG; Lasmar MF; Lasmar LF; Lima PV; Nogueira AF
Transplant Proc; 2009 Apr; 41(3):959-61. PubMed ID: 19376398
[TBL] [Abstract][Full Text] [Related]
31. Sirolimus monotherapy in liver transplantation.
Di Benedetto F; Di Sandro S; De Ruvo N; Masetti M; Montalti R; Romano A; Guerrini GP; Ballarin R; De Blasiis MG; Gerunda GE
Transplant Proc; 2007; 39(6):1930-2. PubMed ID: 17692656
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus monotherapy as maintenance immunosuppression: single-center experience in 50 kidney transplant patients.
Arellano EM; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
Transplant Proc; 2007 Sep; 39(7):2131-4. PubMed ID: 17889115
[TBL] [Abstract][Full Text] [Related]
33. Malignancies after kidney transplantation.
Rascente M; Pisani F; Barletta A; D'Angelo M; Giammaria A; Parzanese I; Rizza V; Iaria G; Famulari A
Transplant Proc; 2005; 37(6):2529-31. PubMed ID: 16182735
[TBL] [Abstract][Full Text] [Related]
34. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
35. Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus.
Mohsin N; Budruddin M; Kamble P; Khalil M; Pakkyarra A; Jha A; Mohammed E; Ahmed H; Ahmed J; Thomas S; Campistol JM; Daar A
Transplant Proc; 2007 May; 39(4):1267-71. PubMed ID: 17524950
[TBL] [Abstract][Full Text] [Related]
36. Sirolimus in pediatric liver transplantation: a single-center experience.
Gibelli NE; Tannuri U; Pinho-Apezzato ML; Tannuri AC; Maksoud-Filho JG; Andrade WC; Velhote MC; Santos MM; Ayoub AA; Marques da Silva M
Transplant Proc; 2009 Apr; 41(3):901-3. PubMed ID: 19376384
[TBL] [Abstract][Full Text] [Related]
37. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular carcinoma following renal transplantation: experience in northern Taiwan.
Chiang YJ; Wang HH; Liu KL; Chu SH; Lee WC
Transplant Proc; 2008 Sep; 40(7):2397-9. PubMed ID: 18790246
[TBL] [Abstract][Full Text] [Related]
39. De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus.
Flechner S; Friend P; Campistol J; Weir M; Diekmann F; Russ G
Transplant Proc; 2009; 41(6 Suppl):S42-4. PubMed ID: 19651296
[No Abstract] [Full Text] [Related]
40. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
